In this discussion with Dr. Noah Weisleder, PhD, from the Weisleder Lab at Ohio State University College of Medicine, and Rich Horgan, founder and CEO of Cure Rare Disease, we’ll delve into the promising research being conducted by Dr. Weisleders’s lab to develop MyoTRIM - a non-viral, protein-based therapy. We’ll discuss findings from the early-stage research, applications for the treatment of various forms of muscular dystrophy, and more.
MyoTRIM is a protein-based therapy being developed through collaboration with Weisleder Lab at Ohio State University College of Medicine and Cure Rare Disease. MyoTRIM delivers an improved version of MG53 and could potentially treat Duchenne muscular dystrophy, Becker muscular dystrophy and various subtypes of Limb Girdle muscular dystrophy, acting as adjunct therapy.
Non-Viral Therapy: MyoTRIM is non-viral, making it suitable for patients with previous gene therapy or antibodies to AAV therapies. Moreover, repeat dosing is possible with this approach.
Inclusive Treatment: It has the potential to treat patients of all ages and with any dystrophin mutation as it acts agnostic of the underlying mutation.
Muscle Protection: Early testing shows MyoTRIM's potential to protect muscle fibers from damage.
Founder & CEO, Cure Rare Disease
Leading researcher from the Weisleder Lab, spearheading MyoTRIM's development